GENMAB
Genmab is a biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Its discovery, development, and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs.
GENMAB
Industry:
Biotechnology Health Care Manufacturing Medical
Founded:
1999-01-01
Address:
Copenhagen, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.genmab.com
Total Employee:
501+
Status:
Active
Contact:
+ 45 7020 2728
Total Funding:
204.3 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
GlaxoSmithKline
GlaxoSmithKline investment in Post-IPO Equity - Genmab
Index Ventures
Index Ventures investment in Venture Round - Genmab
LODH Immunology Fund
LODH Immunology Fund investment in Venture Round - Genmab
BankInvest Biomedical Venture
BankInvest Biomedical Venture investment in Venture Round - Genmab
Dansk Erhvervsinvestering
Dansk Erhvervsinvestering investment in Venture Round - Genmab
Apax Partners France
Apax Partners France investment in Venture Round - Genmab
BankInvest Biomedical Venture
BankInvest Biomedical Venture investment in Venture Round - Genmab
Dansk Erhvervsinvestering
Dansk Erhvervsinvestering investment in Venture Round - Genmab
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-06-07 | Bolt Biotherapeutics | Genmab investment in Post-IPO Equity - Bolt Biotherapeutics | 15 M USD |
Key Employee Changes
Official Site Inspections
http://www.genmab.com Semrush global rank: 1.66 M Semrush visits lastest month: 14.83 K
Unable to get host informations!!!
More informations about "Genmab"
About - Genmab
Learn about Genmab’s commitment to sustainability and the company’s environmental, social and governance commitments and performance. Sustainability & ESG. Careers. Be part of the …See details»
Genmab - Wikipedia
Genmab was founded as a European spin-off of American Biotech company Medarex in February 1999. Danish investment firm BankInvest, under Florian Schönharting, provided the seed investment for the company to start up in Copenhagen. Like Medarex, Genmab began work producing monoclonal antibodies for life-threatening or debilitating diseases. Rising quickly in the Biotech world, Genmab attracted many investors, especially venture capital firms. The compan…See details»
Our Responsibility - Genmab
Genmab is committed to transparency of clinical trial research. We recognize the scientific and ethical value of sharing clinical trial information in a non-biased and timely manner to benefit …See details»
Genmab - Crunchbase Company Profile & Funding
Genmab is a biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Its discovery, development, and manufacturing teams are using cutting-edge technology to create and develop …See details»
Genmab US - Transforming the Future of Antibody-Based Cancer …
Genmab is a biotech company that creates antibody-based treatments for cancer and other serious diseases. United States. Global; Japan; Investors; Company. Featured Making a …See details»
Uniquely Focused on Antibody Science | Genmab US
Genmab is driving the next generation of antibody-based medicines to transform the lives of patients with cancer and other serious diseases. Patients are at the center of all we do. At …See details»
Our Structure Enables Scientific Innovation | Genmab US
Genmab regularly partners with other life science companies, academic institutions, and research organizations to unlock new antibody approaches for treating cancer and other serious diseases. We work collaboratively with our …See details»
Org Chart Genmab - The Official Board
The organizational chart of Genmab displays its 59 main executives including Jan Van de Winkel, Anthony Pagano and Brad Bailey Toggle navigation The Official Board SearchSee details»
Genmab - Overview, News & Similar companies | ZoomInfo.com
Who is Genmab. Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the c reator of multiple …See details»
Our Purpose - Genmab
Genmab's purpose is to improve the lives of patients through innovative and differentiated antibody therapeutics. Our vision Our aspiration for the future is that by 2030, our knock-your-socks-off KYSO antibody medicines ® are …See details»
Genmab Global Reach: 70+ Nationalities, 2,200 Team Members, 4 …
Join Genmab and be part of a diverse team of 2,200 members from 70+ nationalities, making a global impact in the field of healthcare. Genmab Global Reach: 70+ Nationalities, 2,200 Team …See details»
Genmab Information - RocketReach
Genmab is a place where you can be authentically you; you are empowered to innovate, build solutions and execute; you feel cared for and supported. In its totality, this makes working at …See details»
Genmab shuffles C-Suite on commercialization, manufacturing as ...
Aug 19, 2024 Bailey was hired in 2020 to establish Genmab’s commercial organization before the 2021 FDA approval for the cervical cancer antibody-drug conjugate Tivdak, which is …See details»
Genmab A/S: Circling Back On This Complicated Story
1 day ago Genmab was established in 1999 and went public in America in 2019 when it raised net proceeds of $546.5 million at $17.75 per American Depository Share (ADS). These figures …See details»
25 Years of Achievement in Antibody Science | Genmab US
Genmab introduces DuoBody ®, a next-generation bispecific antibody technology platform that could be applied to potential therapies that may target cancer and other serious diseases 2012 …See details»
Genmab to Hold 2024 R&D Update and ASH Data Review Meeting …
2 days ago Media Release. Event to be held virtually via live webcast and archived on www.genmab.com; Copenhagen, Denmark; December 11, 2024 – Genmab A/S (Nasdaq: …See details»
At a Glance - Genmab
Genmab aims to improve people’s lives with antibody therapeutics. Through next-generation technology platforms, transactional research and data sciences, it has created a pipeline …See details»
Two Data Analyses from Clinical Trials Show Epcoritamab …
4 days ago Media Release COPENHAGEN, Denmark; December 9, 2024. Results from Arm 1 of the EPCORE ® NHL-2 trial show treatment with epcoritamab combination led to an overall …See details»
Genmab buys second antibody from Scancell, total tab over $1B
Dec 4, 2024 The deal comes about two years after Genmab snagged its first antibody from Scancell for up to $624M, and it brings Genmab's potential tab to a hefty $1.27 billion.See details»
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy …
5 days ago David Freundel, Senior Director, Global R&D & Portfolio Communications T: +1 609 430 2481; E: [email protected] Andrew Carlsen, Vice President, Head of Investor Relations …See details»